Results of a retrospective study conducted in China assessed the safety and efficacy of ixazomib for multiple myeloma.
Real-world data on the efficacy and safety of oral Ninlaro (ixazomib) -based maintenance therapy revealed the treatment is a favorable option for long-term administration among patients with multiple myeloma (MM) not undergoing transplantation. Findings were published in Cancer Medicine.
Patients with MM have a median survival of at least 10 years, and despite improvements in prognosis, almost all patients will eventually relapse, authors explained. “The paradigm of long-term therapy in MM has been widely accepted, since continuous or maintenance therapy after plateau demonstrated obvious prolonged disease control,” they added.
Ixazomib is an oral proteasome inhibitor (PI) approved for patients who have received at least 1 previous therapy for MM. To retrospectively evaluate the treatment in patients who plateaued after bortezomib-based regimens, researchers assessed real-world data collected from a single institution in China.
A total of 71 patients with newly diagnosed MM (NDMM; n = 37) or relapsing/remitting MM (RRMM; n = 34) were consecutively observed after plateauing between April 2018 and April 2020. All individuals received at least 2 cycles of ixazomib within 60 days of the completion of the induction therapy, researchers wrote.
Median patient age was 63 (IQR 41-80) and the majority of patients were male (60.6%). In addition, all patients received a median of 9 cycles of bortezomib (IQR 6-14; induction phase) and a median of 6 cycles of ixazomib (IQR 2-25; maintenance phase) for a median follow-up time of 26.5 months (IQR 7.1-56.8).
Analyses revealed:
Individual preference was the most frequent reason for discontinuation reported and no AE-associated permanent drug interruptions or deaths were recorded. At the latest follow-up, 12 patients had died of progressive disease (PD) from the RRMM cohort and 5 died of non-PD from the NDMM cohort, researchers said.
“With deepening responses but worsening PN, the ixazomib-based regimen exhibited a good therapeutic efficacy with feasible tolerance,” they wrote. “In addition, responses deepened during maintenance and ≥VGPR during induction have demonstrated the association with prolongation of PFS.”
The population studied in this real-world analysis was older, has worse Eastern Cooperative Oncology Group (ECOG) performance and more terminal renal function compared with populations included in clinical trials.
However, the relatively small number of patients recruited from a single institution mark limitations to the study and future multi-center and larger prospective studies are warranted to verify results.
Overall, the oral weekly regimen examined in this study may offer more flexibility to patients with MM and serve as a more convenient alternative to injectable therapies, authors concluded.
Reference
Shen M, Zhang J, Tang R, et al. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study. Cancer Med. Published online October 16, 2021. doi:10.1002/cam4.4313
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More